Literature DB >> 1683219

Calcium antagonists in elderly and black hypertensive patients. Therapeutic controversies.

W Zing1, R K Ferguson, P H Vlasses.   

Abstract

Calcium antagonists are now recommended as monotherapy for the treatment of mild to moderate essential hypertension by the Joint National Committee (JNC) on the Detection, Evaluation, and Treatment of High Blood Pressure. Based on a statement in the 1988 JNC report that black and elderly patients tend to respond better to calcium antagonists, we reviewed the literature to examine the predictive value of age and race to the antihypertensive response of calcium antagonists. The majority of studies we reviewed failed to substantiate the JNC statement and well-promulgated reports in the literature suggesting preferential action of calcium antagonists in the elderly, or their superiority when compared with diuretics, beta-adrenergic blockers, and angiotensin-converting enzyme inhibitors. Although not noted by the JNC, pretreatment blood pressure appeared to be an important predictor of the antihypertensive response to calcium antagonists. The literature reviewed indicates that calcium antagonists have comparable efficacy in black and white hypertensive patients. However, the limited comparative studies reviewed support the JNC statement that, as with diuretics, blacks have a greater antihypertensive response with calcium antagonists than with beta-adrenergic blockers or angiotensin-converting enzyme inhibitors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683219

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

Review 1.  Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.

Authors:  Julie A Johnson
Journal:  Circulation       Date:  2008-09-23       Impact factor: 29.690

2.  Calcium channel antagonists in the modern era of coronary thrombolysis: benefit or detriment?

Authors:  J A Foley; R C Becker
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 3.  The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?

Authors:  M C Ruddy
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

4.  Comparison of nifedipine and propranolol as second line agent for hypertension in black Kenyans.

Authors:  N R Poulter; J E Sanderson; A V Thompson; P S Sever; C L Chang
Journal:  BMJ       Date:  1993-03-06

Review 5.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.

Authors:  R I Ogilvie; E D Burgess; J R Cusson; R D Feldman; L A Leiter; M G Myers
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

6.  Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.

Authors:  John H Cleator; Matthew T Duvernay; Michael Holinstat; Nancy E Colowick; Willie J Hudson; Yanna Song; Frank E Harrell; Heidi E Hamm
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

Review 7.  Calcium antagonists in the elderly.

Authors:  J G Kelly; K O'Malley
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

8.  Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol.

Authors:  B I Hoffbrand; K A Earle; J G Nievel; L J Restrick; N J Simmonds
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.